MUTANT
YK-11
Description:
Puretech Mutant YK11 (SARMS) contains YK11, a synthetic steroidal selective androgen receptor modulator that binds to androgen receptors and has been shown in preclinical models to promote muscle cell differentiation and growth. Unlike classical anabolic steroids, YK11 is characterized as a partial androgen receptor agonist with additional myostatin‑inhibiting activity via upregulation of follistatin, which has made it of interest in experimental settings involving muscle mass and strength. The product is presented as 10 mg capsules, 30 per bottle, and is intended strictly for research use where permitted by law.
Important: The points below reflect potential or hypothesized effects from preclinical and limited experimental data; they do not constitute approved medical claims, and YK11 is not authorized as a therapeutic in most countries.
- May promote increases in lean muscle mass and myogenic differentiation in cell and animal models, likely through combined androgen receptor activation and myostatin inhibition.
- May help counteract muscle wasting in specific experimental models (such as sepsis‑related muscle atrophy) by modulating inflammatory markers and myostatin–follistatin signaling.
- Is being investigated within the broader SARM class, which in general has been explored for potential benefits on strength, body composition, and functional capacity, though robust human data for YK11 specifically are lacking.
- YK11 is not approved for human consumption, and long‑term safety, toxicity profile, and interaction data in humans are not well defined; regulatory agencies and clinical experts advise against its non‑clinical use.
- Preclinical and anecdotal reports raise concerns about potential adverse effects, including suppression of endogenous testosterone, possible liver toxicity at higher exposures, cardiovascular strain, and neurotoxicity with changes in hippocampal neurochemistry and memory impairment.
- As with other SARMs and experimental performance‑enhancing agents, there is a risk of unknown or severe side effects, contamination or mislabeling in the supply chain, and sanctions under anti‑doping regulations; this product should be kept out of reach of children and handled only by qualified personnel in compliant research environments.
- YK11 is not approved for human consumption, and long‑term safety, toxicity profile, and interaction data in humans are not well defined; regulatory agencies and clinical experts advise against its non‑clinical use.
- Preclinical and anecdotal reports raise concerns about potential adverse effects, including suppression of endogenous testosterone, possible liver toxicity at higher exposures, cardiovascular strain, and neurotoxicity with changes in hippocampal neurochemistry and memory impairment.
- As with other SARMs and experimental performance‑enhancing agents, there is a risk of unknown or severe side effects, contamination or mislabeling in the supply chain, and sanctions under anti‑doping regulations; this product should be kept out of reach of children and handled only by qualified personnel in compliant research environments.
Puretech Mutant YK11 delivers lab‑grade excellence with third‑party COA for >99% purity and zero impurities. GMP manufacturing, identity confirmation via mass spectrometry, and stability testing guarantee potency through the full cycle. Bottled in UV‑protective packaging for maximum efficacy—research‑ready reliability.